-
clinically. We will develop cancer biomarkers through statistical models, including AI driven strategies, to predict highly aggressive tissue molecular signatures for mapping future GBM relapse, linking
-
develop cancer biomarkers through statistical models, including AI driven strategies, to predict highly aggressive tissue molecular signatures for mapping future GBM relapse, linking imaging features
-
to identify the key factors controlling enzyme performance in complex mixtures. Molecular modelling will be used to interpret experimental trends and support the development of improved process
-
physiologically relevant models e.g. human airway epithelial air liquid interface using cells isolated from different patient groups combined with molecular biology approaches to mechanistically determine the key